Newest Paper on Laparoscopic Single Site Ovarian Cystectomy Online Now!

FOR IMMEDIATE RELEASE

MESA, Ariz. — January 1, 2026

We’re thrilled to announce the publication of a groundbreaking systematic review and meta-analysis led by Dr. Greg Marchand and the dedicated research team at the Marchand Institute for Minimally Invasive Surgery! Titled “Laparoendoscopic Single-Site Surgery Versus Conventional Laparoscopic Surgery in Ovarian Cystectomy: A Meta-Analysis”, this comprehensive study compares two advanced minimally invasive techniques for removing benign ovarian cysts — Laparoendoscopic Single-Site Surgery (LESS) (using a single small incision, often hidden at the umbilicus for superior cosmetic results) and Conventional Laparoscopic Surgery (CLS) (using multiple small incisions). Analyzing data from 9 studies involving 1,368 women, the meta-analysis reveals compelling insights:

LESS is associated with longer operative times (by about 9.4 minutes on average), likely due to the technical demands of working through a single port.
However, patients undergoing LESS benefit from a shorter hospital stay (reduced by approximately 0.26 days).
Importantly, there are no significant differences in key safety outcomes: postoperative pain scores (at 6 and 24 hours), estimated blood loss, need for opioid analgesics, drop in hemoglobin levels, or overall complication rates.

These findings strengthen the evidence that LESS is a safe, effective, and viable alternative to conventional laparoscopy for women with benign ovarian cysts — offering faster recovery and excellent cosmetic advantages while maintaining comparable safety and pain profiles. This work adds valuable high-level evidence to the field of minimally invasive gynecologic surgery and reflects the Marchand Institute’s ongoing commitment to advancing women’s health through rigorous, volunteer-driven research. Read the full open-access paper for free today:

PubMed Central (PMC) (recommended – full text & PDF): https://pmc.ncbi.nlm.nih.gov/articles/PMC12734174/
Direct PDF download: https://pmc.ncbi.nlm.nih.gov/articles/PMC12734174/pdf/jcm-14-08739.pdf
Published in Journal of Clinical Medicine (December 10, 2025) – DOI: 10.3390/jcm14248739

We invite clinicians, researchers, and patients interested in the latest advancements in minimally invasive surgery to explore this important contribution. A huge thank you to our incredible team of researchers, students, and collaborators who made this possible — all volunteer efforts dedicated to improving outcomes for women everywhere! Visit us at marchandinstitute.org to learn more about our ongoing research, educational programs, and mission to push the boundaries of minimally invasive techniques.

About Dr. Greg Marchand

Greg J. Marchand, MD, FACS, FACOG, FICS, is a dual board-certified obstetrician-gynecologist and minimally invasive gynecologic surgeon practising in Mesa, Arizona. He holds the ABOG Focused Practice Designation in Minimally Invasive Gynecologic Surgery and directs the Marchand Institute for Minimally Invasive Surgery, a 501(c)(3) tax-exempt non-profit research and educational corporation (EIN 42-2857240). He is Program Director of an SLS-accredited fellowship in Minimally Invasive and Robotic Gynecologic Surgery, holds three issued United States patents, and has served as Principal Investigator on eight FDA clinical trials. His systematic reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised with the Cochrane Risk of Bias 2 tool. He accepts no industry funding for his research.